tuberculous pleurisy
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Male and female inpatient aged 15 to 70 years or older depends on the health condition; (2) patients diagnosed with tuberculous pleurisy by WS 288-2017, who received thoracoscopic or thoracotomy treatment, or suspending patients with tuberculous pleurisy, who received thoracoscopic examination; (3) the main index of lung function was > 50%; (4) no abnormality of the main organs in laboratory examination; (5) ASA anesthesia risk I to III classification, the systemic state tolerated operation risk; (6) those who are willing to undergo surgery; (7) willing to cooperate with the investigation and follow-up and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) severe and extensive pulmonary tuberculosis; (2) those who have not received regular anti-tuberculosis treatment; (3) respiratory depression, airway obstruction or tissue hypoxia; (4) lung function was significantly impaired, with major indicators such as FVC, FEV1 and MVV all <40%. (5) patients with severe extrapulmonary tuberculosis who could not be cured even after removal of pulmonary lesions; (6) complicated with other serious diseases such as diabetes, hyperthyroidism, and severe liver and kidney diseases; (7) patients with congestive heart failure or renal failure; (8) patients with history of malignant tumor and immune system diseases; (9) Parkinson's disease is severe enough to increase the likelihood of falling or endanger recovery; (10) patients with severe alzheimer's disease or other mental illness who cannot cooperate with the examination; (11) had acute myocardial infarction in the past three months; (12) systemic infected persons with obvious pulmonary infection symptoms or other poorly controlled diseases; (13) combined with poorly controlled coagulation diseases; (14) other operation schedule is affected and the operation cannot be performed; (15) pregnant or lactating women; (16) drug and/alcohol abusers; (17) participants in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SEN, SPE, ACC, AUC of ROC; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visceral pleural thickness;Parietal pleural thickness; | — |
Countries
China
Contacts
Xi'an Chest Hospital